Earnings ·
Elanco raises full-year revenue and EPS guidance after Q3 results beat with $1.265B in sales
ELANElanco Animal Health Inc
Elanco Animal Health reported third-quarter revenue of $1.265 billion, an 11% increase year-over-year, driven by strong demand for Zenrelia and Credelio Quattro. Adjusted EPS came in at $0.27, beating expectations, while adjusted EBITDA reached $243 million with a margin expansion to 19.5%. The company raised its full-year revenue guidance to $5.155 billion–$5.18 billion and increased the adjusted EPS target to $1.17–$1.20. Net leverage improved to 2.9x, unlocking capital allocation flexibility. Elanco Animal Health is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets.